Stars are more colorful than you think! Patience will reveal them; head outside tonight to see summer’s multi-hued stars.

5 analysts have expressed a variety of opinions on Arcturus Therapeutics ARCT over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes their ...

5 analysts have expressed a variety of opinions on Arcturus Therapeutics (NASDAQ:ARCT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) and Pharvaris (PHVS – Research ...

Following Saturn is Venus, rising in New York at 2:51 a.m. on July 25. Venus is in Taurus, and so bright that it is ...

By Deane Morrison In August, Mars gets lost as it sinks deep into the sun’s afterglow. Meanwhile, Jupiter climbs above the predawn eastern horizon to join brilliant Venus. Early in the month, Venus ...

In a report released yesterday, Pete Stavropoulos from Cantor Fitzgerald maintained a Buy rating on Axsome Therapeutics, with a price target of $153.00. The company’s shares closed yesterday at ...

Get the detailed quarterly/annual income statement for Arcturus Therapeutics Holdings Inc. (ARCT). Find out the revenue, expenses and profit or loss over the last fiscal year.

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis continues the discussion on mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines and ...